ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ₹7730 at the close on 23 Oct 2026, 12:00 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
50
out of 100
P/E
53.2x
forward 35.5x
1-year return
-3.0%
Dividend yield
0.26%
Apollo Hospitals Enterprise Limited in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Apollo Hospitals runs a network of multi-specialty hospitals across India, with a large retail pharmacy chain (Apollo Pharmacies), diagnostics, and the Apollo Clinics primary-care network feeding patients into its beds. The integrated model is the moat: a pharmacy and diagnostics footprint that captures a patient's repeat spending and routes complex cases to its own tertiary hospitals, which is hard to replicate with standalone hospitals. Revenue grew 20.6% over the trailing period at a 12.2% operating margin, and the market is paying 52.4 times trailing earnings and 34.9 times forward, so the multiple assumes the margin expansion from the pharmacy and digital segments continues. Demand tailwinds from rising private healthcare spending in India are real, but the stock is priced for execution, so the question for a deeper look is whether operating margins can keep widening while the rollout of new beds and clinics continues.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
moderate
Rich valuation multiples
P/E of 52.4 and EV/EBITDA of 31.5 leave little room for error, with the stock trading 1.5% below the ACCE price target of ₹7844.00 after a 34.1% earnings rise.
moderate
Thin margin cushion
Net margin of 7.9% against a gross margin of 35.2% means most revenue is absorbed by operating and financing costs, so modest pressure would hit earnings hard.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-10-22 · prices to Oct 23, 2026
Why it could do well
Revenue grew 20.6% over the latest year, well ahead of its 14.9% average annual pace across the past five years.
Analysts' mean price target of INR 9836.50 sits 29.4% above the current share price, suggesting room for upside in their view.
The latest quarter beat expectations, with earnings per share of 40.37 against 38.31 expected, a 5.4% surprise.
Why it could disappoint
At a trailing P/E of 52.4x, investors are paying a steep premium for each rupee of earnings the company currently produces.
A net margin of 7.9% leaves little cushion, so any slowdown in revenue could hit profits quickly.
The share price of ₹7730.00 sits 1.5% below the ACCE price target of ₹7844.00, so the stock has limited discount to our own target.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where APOLLOHOSP.NS's valuation models land
Price
₹7730.00
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.